MedTrace Logo

Cyclophosphamide Drug Interaction Study In Cancer Patients

NCT00334646 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-11-17

No results posted yet for this study

Summary

This study is designed to evaluate the potential pharmacokinetic interaction between oral GW679769 and IV (intravenous) cyclophosphamide when administered to cancer patients.

Conditions

  • Nausea and Vomiting, Chemotherapy-Induced

Interventions

DRUG

Oral GW679769

150mg oral, once daily on days 1-3

DRUG

IV Cyclophosphamide 500-700mg/m2

IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-10
Primary Completion
2009-10-14
Completion
2009-10-14

Countries

  • United States
  • New Zealand
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00334646 on ClinicalTrials.gov